Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 8/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.61 |
| ▸ | PHLPP1 | O60346 | 2/20 | 0.61 |
| ▸ | ILK | Q13418 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612809 | 0.93 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5441388 | 0.86 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL19659847 | 0.86 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL29393858 | 0.86 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL3270839 | 0.86 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL407517 | 0.86 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5771699 | 0.82 | AKT1 (0.69) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL967402 | 0.82 | AKT1 (0.41) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5773831 | 0.81 | GSTO1 (0.47) | ALOX5NR1I2 | |
| SCHEMBL18212526 | 0.81 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | claimed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | claimed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | claimed |
| WO-2004045534-A2 | CHROMAN DERIVATIVES FOR THE REDUCTION OF INFLAMMATION SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | claimed |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | MONSANTO TECHNOLOGY LLC | 2004-05-20 | — | — | US | claimed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-7034054-B2 | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols | GALILEO PHARMACEUTICALS, INC. (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20040152764-A1 | Compositions and methods for the prevention and treatment of cerebral ischemia | MILLER GUY M (US) | 2004-08-05 | — | — | US | disclosed |
| WO-2004045534-A2 | CHROMAN DERIVATIVES FOR THE REDUCTION OF INFLAMMATION SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | MONSANTO TECHNOLOGY LLC | 2004-05-20 | — | — | US | disclosed |
| WO-2002047680-A9 | USE OF TOCOPHEROL, METABOLITES OR DERIVATIVES THEREOF OR FLAVONOID METABOLITES OR DERIVATIVES THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TISSUE ISCHEMIA | GALILEO LAB INC (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20020143049-A1 | Compositions and methods for the prevention and treatment of cerebral ischemia | PTC THERAPEUTICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002047680-A2 | USE OF TOCOPHEROL, METABOLITES OR DERIVATIVES THEREOF OR FLAVONOID METABOLITES OR DERIVATIVES THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TISSUE ISCHEMIA | GALILEO LABORATORIES, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143049-A1 | Compositions and methods for the prevention and treatment of cerebral ischemia | EBP, NDUFB3, ECH1 | AKT1 2184/4885PDPK1 2120/4885PHLPP1 3289/4885 |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | AKT1 3368/4885PDPK1 4164/4885PHLPP1 3614/4885 |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | AKT1 3368/4885PDPK1 4164/4885PHLPP1 3614/4885 |
| US-20040152764-A1 | Compositions and methods for the prevention and treatment of cerebral ischemia | EBP, NDUFB3, ECH1 | AKT1 2184/4885PDPK1 2120/4885PHLPP1 3289/4885 |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | AKT1 3301/4885PDPK1 1893/4885PHLPP1 2723/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | AKT1 3502/4885PDPK1 2127/4885PHLPP1 2278/4885 |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | CCL2, MPO, MB | AKT1 4329/4885PDPK1 2675/4885PHLPP1 3569/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | AKT1 3502/4885PDPK1 2127/4885PHLPP1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.